1 | 08:00-08:05 |
Welcome Speech |
|
1 | 08:05-08:20 |
Application of PARP inhibitor in AR variant positive CRPC |
|
||||
2 | 08:20-08:35 |
Pathology and treatment of CRPC |
|
||||
3 | 08:35-08:50 |
Modelling and Targeting CRPC or NEPC progression from Hormone-Naïve Prostate Cancer |
|
||||
4 | 08:50-09:05 |
iTind A New Comer of Minimally Invasive Surgery for BPH |
|
||||
5 | 09:05-09:10 |
Discussion |
1 | 09:10-09:25 |
Regenerating Urethral Striated Muscle by CRISPRi/dCas9-KRAB-Mediated Myostatin Silencing for Obesity-Associated Stress Urinary Incontinence |
|
||||
2 | 09:25-09:40 |
Chimeric RNAs in prostate cancer |
|
||||
3 | 09:40-09:55 |
Application of Laparoscopic Surgical Robot System in Radical Prostatectomy & its latest development in APAC Region |
|
||||
4 | 09:55-10:10 |
Prostate Carcinoma Management in Macau |
|
||||
5 | 10:10-10:15 |
Discussion |
1 | 10:25-10:35 |
Tumor-derived exosomal circEAT1 activates TGFβ/SMAD signaling pathway to drive lymphatic metastasis of bladder cancer |
|
||||
2 | 10:35-10:45 |
A novel “3S+f” nephrometry score system to predict the clinical outcomes of nephron-sparing surgery |
|
||||
3 | 10:45-11:00 |
TIPS AND TRICKS IN RETZIUS-SPARING RARP |
|
||||
4 | 11:00-11:10 |
Intra-operative high-resolution specimen PET-CT: leveraging the power of molecular imaging to enhance surgery |
|
||||
5 | 11:10-11:20 |
STRESS URINARY RECCURENCY OR PERSISTANCE AFTER MID-URETHRAL SLINGS:WHATTO DO? |
|
||||
6 | 11:20-11:30 |
Outcome-based patient care through AI-based decision support with the virtual patient in 4D |
|
||||
7 | 11:30-11:35 |
Discussion |
1 | 11:35-11:43 |
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial |
|
||||
2 | 11:43-11:51 |
PD-1 inhibitor Plus Anlotinib for Metastatic Castration Resistant Prostate Cancer: A Real-World Study |
|
||||
3 | 11:51-11:59 |
The action of IGF-1/IGF-1R signal in the progression and thearpy of prostate cancer |
|
||||
4 | 11:59-12:07 |
Predictive value of CRMP4 methylation signature for Gleason Upgrading in Low-risk Prostate Cancer: a retrospective analysis and multi-institutional validation study |
|
||||
5 | 12:07-12:15 |
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity |
|
||||
6 | 12:15-12:23 |
SCNA burden may not be optimal surrogate for response to ICIs |
|
||||
7 | 12:23-12:28 |
Discussion |
1 | 12:28-12:36 |
MRI-measured adipose features as predictive factors for detection of prostate cancer in males undergoing systematic prostate biopsy: A retrospective study based on a Chinese population |
|
||||
2 | 12:36-12:46 |
Pragmatic considerations and challenges in MRI-TRUS guided (transperineal) prostate cancer biopsy |
|
||||
3 | 12:46-12:54 |
CTCs detection for Highly Sensitive and Non-Invasive Diagnosis of Prostate Cancer in PSA Gray Zone |
|
||||
4 | 12:54-13:02 |
Landscape of chimeric RNAs in prostate cancer from Chinese population |
|
||||
5 | 13:02-13:10 |
68Ga-PSMA-11 PET/CT predicts favorable pathological response and pathologically complete resection in high-risk non-metastatic prostate cancer patients receiving neoadjuvant chemohormonal therapy followed by radical prostatectomy: a prospective pilot study |
|
||||
6 | 13:10-13:18 |
Ileal Ureter Replacement Combined with Ileal Augmentation Cystoplasty for Ureteral Strictures with Bladder Contracture: The Initial Experience and Outcome |
|
||||
7 | 13:18-13:23 |
Discussion |
1 | 13:23-13:31 |
Establishment of IMDC-Olig Model Based on Overall Mortality to Optimize Candidates Selection for Cytoreductive Nephrectomy: Analysis of an International Multicenter Registry |
|
||||
2 | 13:31-13:39 |
Proteobacteria derived exosomal PIWI-interacting RNA-36766 accelerates accumulation and immune suppression of myeloid-derived suppressor cells in renal cell carcinoma |
|
||||
3 | 13:39-13:47 |
Suppression of STING triggers ER stress-mediated pyroptosis and promotes antitumor immunity in renal cell carcinoma |
|
||||
4 | 13:47-13:55 |
ZDHHC2-mediated AGK S-palmitoylation inactivates PTEN to reduce sensitivity to sunitinib in ccRCC |
|
||||
5 | 13:55-14:03 |
TGFβ inhibitors can regulate CAF collagen synthesis and inhibit the progression of renal clear cell carcinoma |
|
||||
6 | 14:03-14:11 |
Artificial intelligence for diagnosing and predicting survival of patients with renal cell carcinoma: Retrospective multi-center study |
|
||||
7 | 14:11-14:16 |
Discussion |
1 | 14:16-14:24 |
Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer |
|
||||
2 | 14:24-14:32 |
Silencing Trim59 inhibits metastasis and epithelial-to-mesenchymal transition via TGF-β/Smad2/3 signaling pathway in bladder cancer cells |
|
||||
3 | 14:32-14:40 |
Immune Microenvironment-Related Microbiome Signature to Predict Prognosis of Bladder Urothelial Carcinoma |
|||||
4 | 14:40-14:48 |
Prevalence and prognostic significance of variant histology in urinary tract tumors: A SEER population-based study |
|
||||
5 | 14:48-14:56 |
A classifier to predict local-recurrence of upper tract urothelial carcinoma after kidney-sparing surgery |
|
||||
6 | 14:56-15:04 |
Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study |
|
||||
7 | 15:04-15:09 |
Discussion |
1 | 15:09-15:14 |
Explainable deep neural network model on predicting urinary continence after Robotic-Assisted Radical Prostatectomy using multiple types of MRI anatomical measurements |
|
||||
2 | 15:14-15:19 |
Chemosensitization and immunology regulation reinforced by acoustic cavitation in prostate cancer |
|
||||
3 | 15:19-15:24 |
The prognosis analysis of osteoblastic metastases, osteolytic metastases and mixed bone metastases in prostate cancer |
|
||||
4 | 15:24-15:29 |
Multiple Radiomics methods based on Multi-parameter MRI to distinguish benign and malignant with PI-RADS≤3 nodules and PSA 4-10ng/ml |
|
||||
5 | 15:29-15:34 |
Combination of Symptoms and Noninvasive Test Parameters for Predicting Detrusor Underactivity in Men with Benign Prostatic Hyperplasia |
|
||||
6 | 15:34-15:44 |
Data 5.0 – Data Acquisition, Translation and Analysis |
|
||||
7 | 15:44-15:49 |
SPTBN1 abrogates renal clear cell carcinoma progression in a GPT2-dependent glycolysis reprogramming manner |
|
||||
8 | 15:49-15:54 |
T.H.R.O.B.V.S. Score - A Comprehensive Model to Predict the Surgical Complexity of Renal Cell Carcinoma With Tumor Thrombus |
|
||||
9 | 15:54-15:59 |
Discussion |
1 | 16:09-16:14 |
Vesicoprostatic Muscle Reconstruction: A Step Further for Immediate and Early Urinary Continence |
|
||||
2 | 16:14-16:19 |
A Prediction Model of Targeted Drug Resistance in Renal Cell Carcinoma Based on Plasma Proteomics Analysis |
|
||||
3 | 16:19-16:24 |
Not Every Minute Counts When the Renal Hilum is Clamped: a “Breaking Point” Exists in Ischemia/reperfusion-induced Oxidative Damage and Kidney Injury in Mice |
|
||||
4 | 16:24-16:29 |
The unique genomic landscape and prognostic mutation signature in Chinese clear cell renal cell carcinoma |
|
||||
5 | 16:29-16:34 |
Inhibition of primary cilia-hedgehog signaling axis triggers autophagic cell death and suppresses malignant progression of VHL wild-type ccRCC |
|
||||
6 | 16:34-16:39 |
Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation: the largest cohort study in China |
|
||||
7 | 16:39-16:44 |
Current progress on the effect of mobile phone radiation on sperm quality: An updated systematic review and meta-analysis of human and animal studies |
|
||||
8 | 16:44-16:49 |
Is absorbable suture superior to permanent suture for sacrocolpopexy |
|
||||
9 | 16:49-16:54 |
Fluoroscopy-free Moses Technology Holmium Laser for Treating Stones Associated with Infundibular Stenosis: a retrospective safety and efficacy cohort study |
|
||||
10 | 16:54-16:59 |
Robotic-assisted laparoscopic bilateral ileal ureter replacement with extracorporeal ileal segment preparation for bilateral extensive ureteral strictures: the initial experience |
|
||||
11 | 16:59-17:04 |
Discussion |
1 | 17:04-17:20 |
Closing Remark |
|